Impact Biomedical Q2 FY26 net loss narrows 95% to $700,000

• Impact Biomedical posted a net loss of $700,000 for the quarter ended June 30, 2026, narrowing 95% year over year.
• Revenue fell 57% to $3,000, reflecting retail sales of its Celios air purification technology.
• Total costs and expenses dropped 39% to $705,000, led by a 78% decline in professional fees to $92,000.
• For the six months ended June 30, net loss narrowed 81% to $2.98 million as revenue rose 43% to $10,000.
• Management flagged substantial doubt about continuing as a going concern, citing plans to monetize intellectual property and tightly control costs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Impact Biomedical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-036601), on August 07, 2026, and is solely responsible for the information contained therein.